Propranolol Extended-Release Capsules Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Capsules
Available Strengths: 60 mg, 80 mg, 120 mg, 160 mg
Reference Brands: Inderal LA®
Category:
Antipsychotropic Drugs
Propranolol is a non-selective beta-adrenergic blocker that inhibits β1 and β2 receptors, reducing heart rate, cardiac output, and blood pressure. It decreases sympathetic nervous system activity, making it effective for hypertension, angina pectoris, arrhythmias, migraine prophylaxis, and essential tremor. The extended-release (ER) capsules provide a steady release over 24 hours, improving compliance and maintaining consistent blood levels. Propranolol ER is also used off-label for performance anxiety and PTSD symptoms.
Propranolol Extended-Release Capsules is available in Extended-Release Capsules
and strengths such as 60 mg, 80 mg, 120 mg, 160 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Propranolol Extended-Release Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Propranolol Extended-Release Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Propranolol Extended-Release (ER) capsules are FDA-approved in the U.S. for treating hypertension, angina pectoris, arrhythmias, migraine prophylaxis, and essential tremor. As a non-selective beta-blocker, it is subject to cardiovascular safety labeling, and extended-release formulations must meet modified-release and bioequivalence standards. U.S. regulations require GMP-compliant manufacturing, stability data, and ongoing pharmacovigilance. In the European Union, propranolol ER is authorized for similar indications under national approvals, with adherence to EMA guidance on beta-blockers. EU-specific requirements include Risk Management Plans (RMPs) and post-marketing surveillance. For dossier-ready Propranolol ER capsules, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing